ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 250 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $796,000 | -17.4% | 32,877 | -20.4% | 0.07% | -17.3% |
| Q4 2021 | $964,000 | +56.0% | 41,294 | +11.1% | 0.08% | +32.8% |
| Q3 2021 | $618,000 | -10.8% | 37,184 | +30.8% | 0.06% | -15.3% |
| Q2 2021 | $693,000 | +3050.0% | 28,426 | +6026.3% | 0.07% | +3500.0% |
| Q2 2020 | $22,000 | +175.0% | 464 | +148.1% | 0.00% | +100.0% |
| Q1 2020 | $8,000 | +33.3% | 187 | +40.6% | 0.00% | 0.0% |
| Q4 2019 | $6,000 | -57.1% | 133 | -66.8% | 0.00% | -66.7% |
| Q3 2019 | $14,000 | +75.0% | 401 | +32.8% | 0.00% | +50.0% |
| Q2 2019 | $8,000 | -11.1% | 302 | +0.7% | 0.00% | 0.0% |
| Q4 2017 | $9,000 | -10.0% | 300 | +18.1% | 0.00% | 0.0% |
| Q3 2017 | $10,000 | 0.0% | 254 | -29.8% | 0.00% | 0.0% |
| Q2 2017 | $10,000 | 0.0% | 362 | +29.3% | 0.00% | -33.3% |
| Q1 2017 | $10,000 | 0.0% | 280 | -18.6% | 0.00% | 0.0% |
| Q4 2016 | $10,000 | – | 344 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |